Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cell Reports Medicine Année : 2022

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma

Julie Rousset
  • Fonction : Auteur

Résumé

Highlights d AXL and c-MET are overexpressed in radiotherapy-and cisplatin-resistant HNSCC d Overexpression of AXL and c-MET contributes to tumor aggressiveness and poor prognosis d Cabozantinib has anti-tumor and anti-metastatic efficacy in mice and zebrafish models d Cabozantinib efficacy is shown on HNSCC biopsies and in one patient after several relapses
Fichier principal
Vignette du fichier
main-4.pdf (5.21 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04237773 , version 1 (11-10-2023)

Identifiants

Citer

Anais Hagege, Esma Saada-Bouzid, Damien Ambrosetti, Olivia Rastoin, Julien Boyer, et al.. Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma. Cell Reports Medicine, 2022, 3 (9), pp.100659. ⟨10.1016/j.xcrm.2022.100659⟩. ⟨hal-04237773⟩
9 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More